NuVasive Expands Cervical Advanced Materials Science™ Portfolio with Launch of Porous Titanium Implant

SAN DIEGO, Sept. 5, 2019 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the commercial launch of Modulus® Cervical, a porous titanium interbody implant for cervical applications. The availability of Modulus Cervical expands the Company’s Advanced Materials Science™ (AMS) portfolio to include both Porous PEEK™ and porous titanium offerings for anterior cervical discectomy and fusion (ACDF) techniques, a commonly performed surgery to address cervical disc degeneration or spinal instability.

NuVasive’s Modulus offerings are part of the Company’s AMS portfolio that represent the future of porous implant technologies. Adhering to the core principles of AMS — surface, structure and imaging — Modulus is intelligently designed to combine the inherent benefits of porosity with the advantageous material properties of titanium.

“Modulus Cervical provides the structural benefits of titanium, an imaging advantage closer to radiolucent materials and a lattice structure that allows for bone in-growth,” said Dr. Michael W. Groff, MD, neurosurgeon at Brigham & Woman’s Hospital. “These characteristics, combined with the implant’s porous surface technology, are unmatched compared to other cervical interbodies on the market.”

Traditional PEEK and titanium implants are limited by the materials from which they are created, which often result in surgeons being forced to make compromises when selecting a spinal implant - a sacrifice of radiolucency for durability or favorable osteogenic properties and a desired stiffness similar to bone. As observed in animal studies, Modulus implants are uniquely designed to provide a favorable environment for bone in-growth, while mimicking a stiffness that is similar to bone and allowing for enhanced visualization on a variety of imaging modalities.

“NuVasive’s expanded AMS portfolio for cervical applications provides surgeons with additional solutions to select the right material for their patient,” said Matt Link, president of NuVasive. “Our delivery of a best-in-class implant for this space is a direct reflection of our efforts to provide better patient outcomes through continued expansion of our cervical portfolio.”

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvasive-expands-cervical-advanced-materials-science-portfolio-with-launch-of-porous-titanium-implant-300911844.html

SOURCE NuVasive, Inc.